Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.msard.2020.102180 http://scihub22266oqcxt.onion/10.1016/j.msard.2020.102180 32408155!7202802!32408155     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mult+Scler+Relat+Disord 2020 ; 42 (ä): 102180 Nephropedia Template TP {{tp|p=32408155|t=2020. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |pdf=|usr=}}{{32408155}} gab.com Text Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod JO: Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=32408155 #FOAvip BACKGROUND: Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have not been described. METHODS AND RESULTS: We report a 57-year old female patient with a relapsing remitting multiple sclerosis under fingolimod treatment who experienced a severe COVID-19 infection in March 2020 (Extended Disability Status Scale: 2.0). Having peripheral lymphopenia typical for fingolimod treatment (total lymphocytes 0.39/nL [reference range 1.22-3.56]), the patient developed bilateral interstitial pneumonia with multiple ground-glass opacities on chest CT. Fingolimod medication was stopped. On the intensive care unit, non-invasive ventilation was used to provide oxygen and ventilation support regularly. Over the following two days, oxygenation improved, and the patient was transferred to a normal ward five days after admission. CONCLUSION: The implications fingolimod has on COVID-19 are complex. As an S1P analogue, fingolimod might enhance lung endothelial cell integrity. In addition, in case of a so-called cytokine storm, immunomodulation might be beneficial to reduce mortality. Future studies are needed to explore the risks and therapeutic effects of fingolimod in COVID-19 patients. Twit Text FOAVip Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod ????Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=32408155 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32408155 #FOAvip English Wikipedia <ref>{{Cite pmid|32408155}}</ref> Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod #MMPMID32408155 Foerch C; Friedauer L; Bauer B; Wolf T; Adam EH Mult Scler Relat Disord 2020[Jul]; 42 (ä): 102180 PMID32408155show ga BACKGROUND: Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have not been described. METHODS AND RESULTS: We report a 57-year old female patient with a relapsing remitting multiple sclerosis under fingolimod treatment who experienced a severe COVID-19 infection in March 2020 (Extended Disability Status Scale: 2.0). Having peripheral lymphopenia typical for fingolimod treatment (total lymphocytes 0.39/nL [reference range 1.22-3.56]), the patient developed bilateral interstitial pneumonia with multiple ground-glass opacities on chest CT. Fingolimod medication was stopped. On the intensive care unit, non-invasive ventilation was used to provide oxygen and ventilation support regularly. Over the following two days, oxygenation improved, and the patient was transferred to a normal ward five days after admission. CONCLUSION: The implications fingolimod has on COVID-19 are complex. As an S1P analogue, fingolimod might enhance lung endothelial cell integrity. In addition, in case of a so-called cytokine storm, immunomodulation might be beneficial to reduce mortality. Future studies are needed to explore the risks and therapeutic effects of fingolimod in COVID-19 patients. |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/complications/diagnostic imaging/*physiopathology/therapy[MESH] |Deprescriptions[MESH] |Female[MESH] |Fingolimod Hydrochloride/*therapeutic use[MESH] |Humans[MESH] |Immunosuppressive Agents/*therapeutic use[MESH] |Middle Aged[MESH] |Multiple Sclerosis, Relapsing-Remitting/complications/*drug therapy[MESH] |Noninvasive Ventilation[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/diagnostic imaging/*physiopathology/therapy[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]Severe COVID-19 infection in a patient with multiple sclerosis treated(epmc).pdf DeepDyve Pubget Overpricing